Number of Employees: > 900
Marlboro, Parliament, L&M, Bond Street, Philip Morris, Drina
Welcome to Philip Morris International’s (PMI) affiliates in Serbia. Our operations comprise the cigarette manufacturer Philip Morris Operations a.d.Nis (PMOP) and Philip Morris Services d.o.o. (PMSE). In total we employ more than 900 people across the country.
In October 2003, PMI acquired Serbia’s largest tobacco factory, DIN “Fabrika duvana” a.d. Niš (DIN). At the time, DIN had over a century of experience in cigarette manufacturing. PMI has invested over $800 million in Serbian affiliate over the last twelve years, remaining one of the country’s largest investors. The Niš factory is one of the most advanced operations in PMI’s global network of factories.
Today we are the largest tobacco company in the country. Our strong market leadership comes from international brands from the Philip Morris International portfolio such as Marlboro, Parliament, L&M, Bond Street, Philip Morris and Next and local brand Drina.
Over the past twelve years we have donated over $ 16 million to community initiatives in Serbia. We are also a significant contributor to developing the local community via support to programs focusing on job creation, education, environmental sustainability and social issues. Our strategic contribution programs aim to support entrepreneurship and startup of small and family businesses and the empowerment of young people in order to motivate them to stay in their communities and actively participate in their development.
Smoking and Health
Tobacco products, including cigarettes, are dangerous and addictive. There is overwhelming medical and scientific evidence that smoking causes lung cancer, heart disease, emphysema, and other serious diseases.
All tobacco products are addictive. It can be very difficult to quit smoking, but this should not deter smokers who want to quit from trying to do so.
Public health officials have concluded that secondhand smoke from cigarettes causes serious diseases in non-smokers, including lung cancer and heart disease. We believe the public health conclusions on secondhand smoke are sufficient to support smoking restrictions in public places.
Philip Morris International (PMI) supports comprehensive regulation of tobacco products based on the principle of harm reduction.
To be effective, tobacco regulatory policy must be evidence-based, apply to all tobacco products, and should take into account the views of all legitimate stakeholders including public health authorities, government finance authorities, tobacco manufacturers, and other members of the tobacco supply chain. Regulatory policy must consider the potential to trigger adverse consequences which undermine public health objectives, such as increasing the demand for illicit cigarettes.
While we support comprehensive, effective tobacco regulation, we do not support regulation that prevents adults from buying and using tobacco products or that imposes unnecessary impediments to the operation of the legitimate tobacco market. In that regard, we oppose measures such as generic packaging, point of sale display bans, total bans on communications to adult consumers, and bans on the use of all ingredients in tobacco products.